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Abstract
Objective—We created a national policy model to evaluate the projected cost-effectiveness of 
multiple hospital-based strategies to prevent MRSA transmission and infection.
Design—Cost-effectiveness analysis using a Markov microsimulation model that simulates the 
natural history of MRSA acquisition and infection.
Patients and setting—Hypothetical cohort of 10,000 adult patients admitted to a U.S. ICU.
Methods—We compared 7 strategies to standard precautions using a hospital perspective: (1) 
active surveillance cultures (ASC); (2) ASC plus selective decolonization; (3) universal contact 
precautions (UCP); (4) universal chlorhexidine gluconate (CHG) baths; (5) universal 
decolonization; (6) UCP + CHG baths; and (7) UCP + decolonization. For each strategy, both 
efficacy and compliance were considered. Outcomes of interest were: (1) MRSA colonization 
Contact information: Courtney A. Gidengil, RAND Corporation, 20 Park Plaza, Suite 920, Boston, MA 02116, Tel: (617) 338-2059 
x8637, Fax: (617) 357-7470, gidengil@rand.org. 
The work presented in this manuscript was presented in part as a poster at the Gidengil CA, Gay C, Huang SS, Yokoe D, Lee GM. 
Optimal Strategies to Prevent Methicillin-Resistant Staphylococcus Aureus (MRSA) Transmission in Hospitals. 48th Annual Meeting 
of the Infectious Diseases Society of America (IDSA), October 21–24, 2010.
The remaining authors have no conflict of interest to report.
NIH Public Access
Author Manuscript
Infect Control Hosp Epidemiol. Author manuscript; available in PMC 2016 January 01.
Published in final edited form as:






















averted; (2) MRSA infection averted; (3) incremental cost per colonization averted; (4) 
incremental cost per infection averted.
Results—1,989 cases of colonization and 544 MRSA invasive infections occurred under 
standard precautions per 10,000 patients. Universal decolonization was the least expensive 
strategy and was more effective compared to all strategies except UCP + decolonization and UCP 
+ CHG. UCP + decolonization was more effective than universal decolonization, but would cost 
$2,469 per colonization averted and $9,007 per infection averted. If MRSA colonization 
prevalence drops from 12% to 5%, ASC plus selective decolonization becomes the least expensive 
strategy.
Conclusions—Universal decolonization is cost-saving, preventing 44% of cases of MRSA 
colonization and 45% of cases of MRSA infection. Our model provides useful guidance for 
decision makers choosing between multiple available hospital-based strategies to prevent MRSA 
transmission.
Background
Methicillin-resistant Staphylococcus aureus (MRSA) has become a major problem for U.S. 
healthcare facilities over the past 20 years.1,2 MRSA colonization is associated with 
increased risk of infection even after hospital discharge,3 worse clinical outcomes,4–8 and 
higher costs of care.5–9 Healthcare-associated infections (HAI) have been identified as a 
focus area in Healthy People 2020, with reduction of invasive healthcare-associated MRSA 
infections named as a top priority.10
Many strategies can be used to reduce the risk of MRSA transmission and infection. Active 
surveillance cultures (ASC) can be used to screen patients, with isolation of identified 
MRSA carriers. This strategy can be combined with decolonization of patients with 
chlorhexidine gluconate (CHG) baths, with or without mupirocin to the nares, to further 
reduce the risk of transmission and infection within carriers. At the other extreme, 
depending on factors such as the prevalence of MRSA among patients entering a particular 
hospital, a more effective strategy might be to simply isolate and/or decolonize all patients 
who enter a hospital regardless of MRSA status.
Decision-makers are thus faced with a wide variety of strategies while considering the cost 
and effectiveness of each strategy. Decision analytic models have increasingly been used to 
evaluate the potential impact of health policy questions,11–13 by comparing the projected 
outcomes and costs of alternative strategies.14 Models are particularly useful when it is 
impractical to support multiple clinical trials to compare a range of strategies. In real world 
settings where healthcare facilities consider a range of strategies under constrained 
resources, a comprehensive model that brings together all available strategies would aid 
decision-making at both the local and national levels. We created a national policy model to 
evaluate the projected cost-effectiveness of multiple hospital-based management strategies 
to prevent MRSA transmission and infection.
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We developed a Markov microsimulation model using TreeAge Pro (TreeAge Software Inc. 
2014, Williamstown, MA) for a hypothetical cohort of 10,000 patients admitted to intensive 
care units (ICUs) in the U.S. The model yields a hospital perspective analysis as the cohort 
moves through hospitalization and post discharge. We simulate the natural history of MRSA 
colonization and infection using a sequence of daily transitions among health states (Figure 
1) over a 1-year time horizon. MRSA colonization is defined as a health state in which a 
patient carries the bacteria, but has no clinical infection. MRSA infection occurs when a 
patient develops an invasive infection.
Some patients are colonized and/or infected with MRSA at admission (Table 1), while 
others face a daily risk of acquiring MRSA colonization based on the prevalence of MRSA 
in the ICU. As overall MRSA colonization prevalence increases, we assume a higher risk of 
acquiring MRSA colonization among non-colonized patients. In our base case analysis, we 
assume that the average ICU prevalence is 12% (Table 1); we also consider the impact of 
lower (5%) and higher (20%) prevalence in alternative analyses.
Patients with MRSA infection either die, or remain persistently infected until treatment is 
complete. If infected patients complete treatment, they are no longer colonized but can be 
recolonized and reinfected. Any patients who are discharged from the hospital and who are 
still colonized (either due to persistent colonization or because of recolonization) can remain 
uninfected or develop an MRSA infection post-discharge.15,16 Patients who develop a post-
discharge infection are either treated as an outpatient or may require readmission (for MRSA 
bacteremia, for example).
Strategies
We assume a baseline approach of standard precautions (including hand hygiene) plus 
contact precautions for patients known to be MRSA colonized or infected, and compare 7 
distinct ICU-based strategies: (1) ASC on ICU admission (includes contact precautions if 
found to be MRSA colonized); (2) ASC + selective decolonization for identified MRSA 
carriers; (3) universal contact precautions (UCP); (4) universal CHG baths; (5) universal 
decolonization (CHG baths and nasal mupirocin); (6) UCP + universal CHG baths; and (7) 
UCP + universal decolonization. The first 5 strategies were chosen after reviewing the 
literature and seeking expert guidance to reflect the most common strategies in ICUs. The 
latter two strategies consist of combinations (UCP + CHG baths; UCP + decolonization) to 
provide insight into the utility of the most aggressive approaches to MRSA control.
For ASC strategies, cultures are obtained on ICU admission and weekly thereafter as long as 
the patient remains in the ICU. We assume use of a standard swab of the nasal mucosa 
plated to chromogenic agar with results available within 1–2 days (to allow time for the lab 
to receive the swab, process it, and report results). If patients screen positive, t hey are 
placed on contact precautions (healthcare workers wear gloves and gowns). With selective 
decolonization, those who screen positive undergo daily CHG baths and twice daily 
mupirocin ointment applied to the nares for a maximum of 5 days or until discharge from 
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the ICU, whichever occurs first. In contrast, universal strategies are applied to all ICU 
patients. If the universal CHG strategy is selected, we assume all patients are bathed daily 
with CHG for the duration of their ICU stay. UCP refers to the practice where gowns and 
gloves are used routinely for all patients while in the ICU, unless they are known MRSA 
carriers, which results in the use of contact precautions throughout hospitalization.
For each strategy, both efficacy and compliance are considered. Efficacy is the strategy’s 
ability to reduce risk of MRSA colonization or infection under ideal circumstances. Less-
than-perfect compliance mitigates the overall effectiveness of each intervention, reflecting 
real-world conditions. We consider 3 types of efficacy in our model (Fig 1). For barrier-
based strategies that use contact precautions, we assume a lower risk of transmission from 
carriers to non16 carriers, which lowers colonization pressure and reduces the risk of MRSA 
acquisition. Barrier-based strategies are assumed to have no impact on either colonization or 
infection among individuals with pre-existing colonization. For decolonization-based 
strategies, we assume a reduction in the probability of ongoing colonization and subsequent 
infection in previously colonized individuals. We also assume decolonization-based 
strategies reduce the risk for MRSA acquisition among non-colonized patients by lowering 
overall MRSA colonization prevalence. For strategies that rely on ASC, we assume that 
contact precautions with or without selective decolonization are implemented once test 
results are available. False negative test results and the delay in implementation both lead to 
lower estimates of efficacy compared to empiric strategies such as universal CP and 
universal decolonization.
Costs
We consider the following costs in the model: (1) inpatient medical costs attributable to 
MRSA infection; (2) outpatient medical costs attributable to MRSA infection (both for 
outpatient treatment of inpatient infection, as well as for infections that occur after 
hospitalization due to colonization acquired while hospitalized); and (3) intervention costs. 
We estimated costs and attributable length of stay due to infection based on literature review 
and the model was calibrated accordingly. If a patient develops a post-discharge infection 
and is then readmitted, all subsequent hospitals costs are considered attributable to MRSA. 
Outpatient costs for MRSA infection include the cost of an outpatient visit (average 1.5 
visits) and cost of oral antibiotic therapy (trimethoprim-sulfamethoxazole, clindamycin, or 
doxycycline for an average duration of 7 days). Cost estimates are based on dollar values 
from 2013 by using the medical care component of the consumer price index to account for 
inflation.17 Future costs are discounted at an annual rate of 3%.
Outcomes
Outcomes of interest are: (1) cases of colonization averted; (2) cases of infection averted; (3) 
incremental cost per colonization averted; and (4) incremental cost per infection averted. 
The number of cases of colonization averted include those patients who were colonized on 
admission to the ICU and subsequently became decolonized. Cases of infections prevented 
include those infections avoided within a colonized patient (through decolonization), as well 
as those prevented by decreasing colonization pressure (through e ither decolonization or 
contact precautions). The incremental cost per case of colonization or infection averted is 
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calculated as the cost difference for a given strategy compared to the cost of the next least 
expensive strategy, divided by the difference in the number of cases (of colonization or 
infection) prevented by the two strategies.
Uncertainty
Estimates used for model parameters were based on the best available estimates in the 
literature (Table 1). We also sought input from key experts through the CDC Prevention 
Epicenters program at their meeting on August 18, 2010. We presented estimates for key 
parameters, including MRSA transmission rates, infection rates, efficacy of interventions, 
compliance, and costs, and sought their feedback. We also convened a smaller formal expert 
panel in order to seek further input and validate our estimates.
To account for first order uncertainty, we use a microsimulation model to capture the 
stochastic nature of events among individuals in the cohort. We also consider 2nd order 
uncertainty, or parameter uncertainty, by using probabilistic sensitivity analysis to vary the 
following parameters concurrently: (1) probability colonization and infection at admission; 
(2) probability of acquiring colonization per day if not colonized; (3) attributable length of 
stay due to infection as well as baseline length of stay in uninfected patients; (4) efficacy of 
each intervention; (5) risk of post-discharge infection if colonized; (6) cost of infection; and 
(7) cost of each intervention strategy. We use beta distributions for probabilities, log normal 
distributions for length of stay and cost, and triangular distributions for risk of post-
discharge infection. Our Markov microsimulation model was run for 10,000 cohorts with 
10,000 patients each to evaluate the robustness of our findings for the cost-effective 
strategies. Incremental costs and effectiveness estimates for each of the 10,000 cohorts are 
depicted on a scatterplot. We also calculated a proportion for how often the strategy of 
interest was more effective and cost saving compared to the next most expensive strategy.
Results
Base case scenario
In the absence of MRSA prevention strategies, 1,989 cases of colonization and 544 invasive 
infections occurred in a cohort of 10,000 patients admitted to ICUs. Strategies involving 
universal contact precautions paired with another intervention were the most effective. UCP 
+ decolonization averted the greatest number of cases of MRSA colonization (1,107, or 
56%) and infection (312, or 57%) per 10,000 patients, while UCP + universal CHG was the 
next most effective strategy (890 cases of colonization and 250 infections averted, or 45% 
and 46% respectively), when compared to standard precautions (which includes CP for 
known MRSA carriers) (Table 2).
Strategies without decolonization − meaning ASC + selective contact precautions or UCP 
alone − were the least effective strategies. Among strategies involving decolonization (with 
chlorhexidine +/− mupirocin), ASC testing + selective decolonization of MRSA carriers, 
universal CHG, and universal decolonization prevented more cases of MRSA than standard 
precautions, but were not the most effective strategies.
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The total medical cost associated with MRSA infection in t his hypothetical cohort of 10,000 
patients admitted to the ICU was $8.16 million (we assume that colonization itself does not 
result in higher medical costs in the absence of prevention strategies). Strategies without 
decolonization − UCP or ASC + selective CP− were the most expensive, with net costs of 
$8.15 million and $6.56 million respectively. The next most expensive were UCP + CHG, 
UCP + decolonization, and universal CHG. Universal decolonization alone had the lowest 
net cost ($5.35 million), including intervention cost ($0.78 million) and costs saved due to 
MRSA infection prevention ($3.59 million). ASC testing plus selective decolonization 
resulted in decreased intervention costs but also decreased savings due to less effective 
disease prevention.
Universal decolonization was cost saving overall and prevented 44% of cases of 
colonization and 45% of cases of infection. The next best strategy was UCP + 
decolonization, which resulted in incremental cost-effectiveness ratios of $2,469 per 
colonization averted and $9,007 per infection averted compared to universal decolonization. 
All other strategies were dominated (more costly and less effective).
Impact of MRSA colonization prevalence
If MRSA prevalence were lowered to 5%, the least expensive and reasonably effective 
strategy became ASC + selective decolonization (Appendix A). Universal decolonization 
was slightly more expensive and could prevent an additional 35 cases of colonization and 8 
cases of infection. UCP + decolonization remained the most effective strategy to prevent 
both colonization and infection, with incremental cost-effectiveness ratios of $834 and 
$49,724 respectively. At a higher prevalence of 20%, results were very similar to the main 
model, with universal decolonization again being the least costly strategy (Appendix B). 
UCP + universal decolonization was the next best strategy with incremental cost-
effectiveness ratios of $719 and $2,329 per additional case of colonization and infection 
prevented. All other strategies were dominated.
Probabilistic Sensitivity Analysis
Universal decolonization is more effective and cost saving compared to standard precautions 
85% of the time for MRSA colonization and infection (Figures 2 and 3). When UCP + 
decolonization is compared to universal decolonization, 24% of the model runs result in 
estimates that are more effective and cost saving for colonization and infection. Furthermore 
95% yielded incremental cost-effectiveness ratios that were <$2,500 per colonization 
averted and <$9,000 per infection averted.
Discussion
We developed a national policy model to evaluate the cost-effectiveness of strategies to 
prevent MRSA colonization and infection. Assuming 4 million ICU visits per year in the 
U.S., our model estimates that 218,000 MRSA infections would occur in absence of any 
intervention (i.e. standard precautions) at a cost of approximately $3.3 billion, similar to 
previously published national estimates.18–20 Our model predicts that universal 
decolonization would prevent 44% of MRSA infections and reduce overall costs by 34% 
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(i.e. by $1.11 billion). UCP + decolonization was more effective than universal 
decolonization, and may be worth considering if the willingness-to-pay threshold is at least 
$2,400 per colonization averted or $9,000 per infection averted. Universal decolonization 
was more effective and less expensive compared to standard precautions, non-
decolonization strategies, or use of universal CHG alone. Decolonization-based strategies 
that utilize both intranasal mupirocin and CHG baths were preferred over other strategies 
even when we varied assumptions about disease probabilities, efficacy, and costs.
Our U.S.-based policy model is one of the first to compare all ICU-based strategies head-to-
head. Other models have typically evaluated a single intervention,21–23 which limits the 
utility for decision-makers who may want to optimize their investment among a range of 
available strategies. A model based in the United Kingdom also evaluated a wide range of 
strategies and found that universal nasal mupirocin alone was the most cost-effective 
strategy.24 However, universal decolonization with both mupirocin and CHG was not 
considered, which is relevant for decision makers in the U.S. We not only consider the costs 
and outcomes associated with MRSA during the initial hospital admission, but the 
subsequent impact post-discharge. This is critically important since much of the infection 
burden following acquisition of MRSA occurs after discharge from the hospital.15,16
Our findings are based on a theoretical model, and are remarkably in line with results from 
recent trials on MRSA control strategies. Huang et al.25 demonstrated that universal 
decolonization of ICU patients was the most effective strategy to decrease bloodstream 
infections (across all pathogens) and reduce MRSA clinical isolates. Our model provides 
further support to this approach by demonstrating that it is cost-saving in addition.
Though we conducted a robust set of sensitivity analyses, there are several limitations to 
consider. First, our model applies to an “average” hospital based on average U.S. estimates. 
Individual healthcare facilities may wish to reconsider the full range of strategies using 
alternative assumptions about MRSA prevalence, costs, and compliance based on local data. 
For example, when we changed the MRSA prevalence to 5%, we found that ASC plus 
selective decolonization became the least expensive strategy. Further, hospitals may be 
constrained by the resources needed for interventions that may not be directly reimbursed by 
payers. However, shorter lengths of stay, lower readmission rates and improved outcomes 
provide a counterbalancing financial incentive from the hospital perspective. The ability of 
hospitals to invest in prevention efforts may vary depending on their calculated return on 
investment.
Second, we did not explicitly consider the horizontal impact of these interventions on 
reducing transmission of other common pathogens, such as vancomycin-resistant 
enterococci. The added benefit of strategies using CHG in preventing transmission and 
infection by organisms other than MRSA would improve the overall cost-effectiveness and 
further incentivize investment of resources for infection prevention.
Third, our model assumes that all patients return to the same hospital for readmissions. In 
reality, patients are often admitted to other facilities that subsequently benefit from the cost 
savings of interventions. This also means that we could not formally consider the potential 
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for decolonization-based strategies to reduce spread of MRSA to other healthcare facilities. 
Such strategies could be tested in community-based models26,27 which capture the 
synergistic effect of coordinated regional efforts to minimize MRSA transmission.
Fourth, our model did not incorporate mupirocin or CHG resistance. One approach to 
incorporate the possibility of resistance would be to decrease the overall efficacy of 
decolonization-based interventions over a longer time horizon. Prolonged mupirocin use 
would very likely lead to the emergence of resistance, which would mitigate the overall 
cost-effectiveness of these interventions unless alternative options such as retapamulin 
became readily available.
Our model did not consider other MRSA infections during the initial admission, such as 
MRSA bacteremia that was not associated with a central line, which could contribute 
substantially to morbidity and costs.28,29 However, it did account for post-discharge MRSA 
bacteremia and subsequent readmissions. Finally, our model was not designed to be a 
dynamic model of MRSA transmission, though we did incorporate estimates for increased 
risk of MRSA transmission as hospital-wide prevalence increases.
In conclusion, our national policy model compares multiple strategies to prevent MRSA 
colonization and infection in an ICU cohort. Universal decolonization is more effective and 
cost saving when compared to all other strategies, except for UCP + decolonization. UCP + 
decolonization may be more effective than universal decolonization alone if decision makers 
are willing-to-pay ~$2,400 per case of MRSA colonization averted or ~$9,000 per case of 
MRSA infection averted. ICUs with a high prevalence of MRSA colonization that are not 
currently using strategies to control MRSA beyond standard precautions may wish to 
consider universal decolonization with or without universal contact precautions, depending 
on local factors such as the baseline prevalence of MRSA colonization and the availability 
of resources.
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*Acquisition of MRSA colonization and subsequent infection can be interrupted at the 
transition indicated by A (by contact precautions preventing transmission of MRSA, and/or 
by decolonization decreasing colonization pressure). MRSA infections can also be 
interrupted at the transitions indicated by B (by decolonization with mupirocin and/or CHG 
preventing infections that would have resulted from colonization in already colonized 
patients.)
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Probabilistic sensitivity analyses of cost per case of colonization prevented under different 
strategies
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Probabilistic sensitivity analyses of cost per case of infection prevented under different 
strategies
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Table 1
Model Variables: Baseline Values and Ranges Used in Sensitivity Analyses
Variable Base Case Distribution Source(s)
Disease costs
Cost of MRSA colonization $0 N/A
Average attributable LOS in days of










Average ICU LOS if no MRSA infection 3 days Log normal 35
Average overall LOS if no MRSA infection 5 days Log normal 35
Cost per hospital day (ICU) $4285 Log normal 36
Cost per hospital day (general ward) $969 Log normal Calibrated to model
Daily cost of treatment of invasive
MRSA infection after hospital discharge
$248 Log normal 37









Log normal Expert consensus
Cost per episode of MRSA infection in outpatient setting* $375 Log normal 17,38,39
Intervention costs
Cost of contact precautions per day $125 per day Log normal 40
Cost of ASC test $13 per test Log normal 26,27
Cost of CHG bath per day $11 per day Log normal 17
Cost of decolonization (CHG + mupirocin) per day $23 per day Log normal 17
Intervention estimates
ASC with selective CP
  Efficacy for preventing colonization








ASC with selective decolonization
  Efficacy for preventing colonization







  Efficacy for preventing colonization








  Efficacy for preventing colonization









  Efficacy for preventing colonization
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Variable Base Case Distribution Source(s)
Sensitivity of ASC testing*** 64% -- 55,56 and expert consensus
Specificity of ASC testing 96% -- 55,56
Prevalence/incidence parameters
MRSA colonization at ICU admission 12% Beta 21,41,52,57–64
MRSA infection at ICU admission 0.6% Beta 65,66
Risk of acquiring MRSA colonization
per hospitalization day among non-
colonized patients based on prevalence











Risk of developing MRSA infection
per hospitalization day among
colonized patients
0.6% Beta 15,16,59,67





















Daily probability of death due to other causes






Risk of developing MRSA infection
per outpatient day among colonized
patients
  <3 months
  3–<6 months





Probability of requiring hospitalization




Based on cost of skin and soft tissue infections
**
We based the estimates for efficacy for preventing infection and compliance with the intervention from the trial from reference 25 (extrapolating 
from the effectiveness result presented in the trial). We then used expert consensus to judge the possible efficacy for colonization based on these 
estimates.
***
We assume that patients are receiving nares swabs only. Per expert consensus, we took an estimate of 92% from the literature for detection of 
MRSA from culture under perfect conditions, and multiplied that by 70% to reflect the sensitivity of nares swabs to detect MRSA colonization.
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